This site is intended for Healthcare Professionals only

New cream for vitiligo

Pharmacy News

New cream for vitiligo

The MHRA recently approved ruxolitinib cream (Opzelura) for non-segmental vitiligo with facial involvement from 12 years of age.

About one in 100 people in the UK live with vitiligo, a chronic autoimmune disease. About 80 per cent of these have non-segmental vitiligo: symmetrical white patches on both sides of the body. 

Increased activity of pathways involving two forms of the enzyme janus kinase (JAK1/JAK2) contribute to the melanocyte destruction that causes vitiligo. Ruxolitinib selectively inhibits JAK1/JAK2.

The SmPC pools data from the TRuE-V1 and TRuE-V2 phase 3 studies. At 24 weeks, 31.0 per cent of patients treated with ruxolitinib cream showed at least a 75 per cent improvement from baseline in the facial Vitiligo Area Scoring Index (F-VASI75) compared with 9.6 per cent of controls. After 52 weeks, 50.3 and 28.2 per cent respectively showed better F-VASI75 scores. 

According to the New England Journal of Medicine (2022; 387:1445-55), 54.8 and 62.3 per cent of patients who applied ruxolitinib cream for 52 weeks in TRuE-V1 and TRuE-V2 respectively developed adverse events. 

The most common adverse events were application-site acne (6.3 and 6.6 per cent respectively), nasopharyngitis (5.4 and 6.1 per cent) and application-site pruritus (5.4 and 5.3 per cent). 

Copy Link copy link button

Pharmacy News

Stay up to date with all the news, learning and insight in the world of pharmacy.

Share: